Bio-Techne and Spear Bio Forge Strategic Partnership to Revolutionize Therapeutic Development Through Ultrasensitive Biomarker Detection
Minneapolis, MN – July 15, 2025 – Bio-Techne Corporation (NASDAQ: TECH), a leading global developer and manufacturer of high-quality reagents and instruments for life science research, and Spear Bio, a pioneer in ultra-sensitive protein detection, today announced a strategic partnership poised to significantly accelerate therapeutic development. This collaboration will leverage Spear Bio’s groundbreaking single-molecule detection technology with Bio-Techne’s extensive portfolio of antibodies, assays, and platforms, enabling researchers and clinicians to identify and quantify biomarkers with unprecedented sensitivity.
The partnership marks a significant advancement in the pursuit of more effective and targeted therapies across a wide range of diseases. The ability to detect biomarkers at exceptionally low concentrations is critical for early disease detection, monitoring treatment efficacy, and understanding complex biological processes that were previously undetectable.
“We are thrilled to join forces with Spear Bio, a company that is truly pushing the boundaries of biomarker detection,” said [Name and Title of Bio-Techne Executive], at Bio-Techne. “This collaboration aligns perfectly with our mission to provide innovative solutions that empower scientific discovery and improve patient outcomes. By integrating Spear Bio’s revolutionary technology with our established platforms, we will unlock new possibilities for understanding disease at its earliest stages and developing the next generation of precision medicines.”
Spear Bio’s proprietary technology is designed to overcome the limitations of traditional biomarker detection methods, offering a substantial increase in sensitivity and a broader dynamic range. This allows for the detection of critical protein markers at picomolar or even femtomolar concentrations, which is crucial for applications such as liquid biopsies, minimal residual disease monitoring, and the study of rare cell populations.
“This strategic partnership with Bio-Techne is a pivotal moment for Spear Bio and a testament to the transformative potential of our ultra-sensitive protein detection platform,” commented [Name and Title of Spear Bio Executive], at Spear Bio. “Bio-Techne’s reputation for quality and their deep expertise in the life sciences market make them an ideal partner. Together, we will empower researchers and pharmaceutical companies with the tools they need to make groundbreaking discoveries and bring life-changing therapies to patients faster.”
The collaboration is expected to result in the development of new, highly sensitive assays and integrated workflows that will be made available to the research and clinical communities. This will enable:
- Earlier and More Accurate Disease Diagnosis: Detecting disease-specific biomarkers at their nascent stages, potentially leading to earlier intervention and improved prognoses.
- Enhanced Therapeutic Monitoring: Precisely tracking the effectiveness of treatments by quantifying the subtle changes in biomarker levels over time.
- Deeper Understanding of Disease Mechanisms: Investigating previously inaccessible biological pathways and cellular events due to limitations in detection sensitivity.
- Advancement of Precision Medicine: Tailoring treatments to individual patients based on highly sensitive biomarker profiles.
This partnership underscores the commitment of both Bio-Techne and Spear Bio to driving innovation in the biopharmaceutical industry and addressing unmet needs in healthcare. The combined strengths of their respective technologies are expected to create a powerful synergy, paving the way for significant advancements in the development of novel diagnostics and therapeutics for a multitude of diseases, including cancer, autoimmune disorders, and infectious diseases.
About Bio-Techne Corporation: Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne consists of its life sciences and diagnostics and automation segments. The life sciences segment includes its protein analysis tools, including immunoassays, antibodies, proteins, and small molecules; cell and gene therapy tools, including cell expansion and editing tools; and advanced diagnostic tools. The diagnostics and automation segment includes its clinical controls, instruments, and informatics solutions. Bio-Techne products are extensively used in preclinical research, clinical diagnostics, and the development of novel therapeutics.
About Spear Bio: Spear Bio is a pioneering biotechnology company dedicated to transforming protein detection through its ultra-sensitive, single-molecule platform. Spear Bio’s technology enables the detection of proteins at previously unattainable levels, opening new frontiers in early disease detection, personalized medicine, and fundamental biological research. The company is committed to developing accessible and powerful tools that accelerate scientific discovery and improve patient lives.
Forward-Looking Statements: This press release contains forward-looking statements. Actual results may differ materially from those projected due to risks and uncertainties, including but not limited to, the success of the partnership in developing and commercializing new products, competitive factors, regulatory approvals, and other factors described in Bio-Techne’s filings with the SEC.
Contact:
Bio-Techne Media Relations [Name] [Title] [Email Address] [Phone Number]
Spear Bio Media Relations [Name] [Title] [Email Address] [Phone Number]
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection’ at 2025-07-15 11:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.